Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Olea europaea pollen extract is a therapeutic allergen extract prepared from olive tree pollen and used in allergen immunotherapy for patients with hypersensitivity to olive pollen. In the cited LETI Pharma clinical study, the product is described as a modified, depigmented and polymerized allergen extract administered by subcutaneous immunotherapy to reduce allergic symptoms and medication use in patients with olive pollen-induced allergic rhinitis or rhinoconjunctivitis, with or without episodic asthma. Its therapeutic effect is based on allergen-specific immune modulation rather than classical receptor pharmacology, aiming to induce tolerance to olive pollen allergens after repeated exposure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on olea europaea pollen extract.